{"groups":[{"description":"Multiple myeloma and amyloidosis patients who did not develop an anti-spike antibody titer of \\>1 S/CO after prior COVID-19 vaccination.","id":"FG000","title":"Cohort 1"},{"description":"Patients with other hematologic malignancies who did not develop an anti-spike antibody titer of \\>1 S/CO after prior COVID-19 vaccination.","id":"FG001","title":"Cohort 2"},{"description":"Patients with multiple myeloma, amyloidosis, or other hematologic malignancy who had a \"weak positive\" response to prior COVID-19 vaccine, defined as an anti-spike antibody titer of 1-2 S/CO.","id":"FG002","title":"Cohort 3"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"52"},{"groupId":"FG001","numSubjects":"51"},{"groupId":"FG002","numSubjects":"16"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"52"},{"groupId":"FG001","numSubjects":"50"},{"groupId":"FG002","numSubjects":"16"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}